Showing results (221-230 of 234) with videos related to

Sort By:
Pageof 24
Blood|July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIAMichele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
Blood|October 26, 2019
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALLKevin J Curran, Steven P Margossian, Nancy A Kernan, et al.
The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.
Blood Advances|December 5, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementationKristine A Frerichs, Christie P M Verkleij, Maria Victoria Mateos, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Advances in Therapy|December 19, 2023
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple MyelomaPhilippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, et al.
The Journal of Clinical Investigation|November 6, 2019
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantationSusan Prockop, Ekaterina Doubrovina, Stephanie Suser, et al.
Journal of Hematology & Oncology|August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic riskKatja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Pageof 24